Cynata Therapeutics Ltd

Research Cynata Therapeutics Ltd (CYP) on Bullrun: market cap AUD 2.92M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCYP
• ExchangeAU
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyAUD
• Market capAUD 2.92M
• Financial periodFY2025
• Net income-AUD 9.39M
• Free cash flow-AUD 8.77M

Valuation Snapshot

latest market cap is AUD 2.92M.

About Cynata Therapeutics Ltd

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease.

Frequently asked questions

What is Cynata Therapeutics Ltd's market cap?

Cynata Therapeutics Ltd's market capitalization is AUD 2.92M.

What does Cynata Therapeutics Ltd do?

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.